Related references
Note: Only part of the references are listed.Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth
Monica Buzzai et al.
CANCER RESEARCH (2007)
Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer
J. Carretero et al.
ONCOGENE (2007)
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Mahvash Zakikhani et al.
CANCER RESEARCH (2006)
MTOR, translation initiation and cancer
Y. Mamane et al.
ONCOGENE (2006)
AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer
Hiroyuki Motoshima et al.
JOURNAL OF PHYSIOLOGY-LONDON (2006)
Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1
Ina Bergheim et al.
GASTROENTEROLOGY (2006)
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin
RJ Shaw et al.
SCIENCE (2005)
The expanding TOR signaling network
DE Martin et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo -: Role of mitochondrial reactive nitrogen species (Publication with Expression of Concern. See vol. 294, pg. 10024, 2019) (Withdrawn Publication. See vol. 294, pg. 13525, 2019)
MH Zou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
RA Gupta et al.
NATURE REVIEWS CANCER (2001)
The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67
III Goodson WH et al.
BREAST CANCER RESEARCH AND TREATMENT (2000)